Annovis Bio Inc (ANVS)

$4.65 0.00 (N/A)
Market Cap 116.88M
Revenue (ttm) 0.00
Net Income (ttm) -24.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 499,600
Avg Vol 2,186,162
Day's Range N/A - N/A
Shares Out 26.50M
Stochastic %K 60%
Beta 1.49
Analysts Strong Sell
Price Target $11.67

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 875 3192
Address:
101 Lindenwood Drive, Suite 225, Malvern, United States
femtomolar
femtomolar Dec. 5 at 4:15 AM
$ANVS The moment I have been waiting for 3 years, thought it would be Biden. Maria, this is the chance you redeem yourself! https://x.com/RepKamlagerDove/status/1996695410174218641?s=20
0 · Reply
Iightning
Iightning Dec. 5 at 12:41 AM
1ightning® Premium Options Alert (Actionable) Ticker: $ANVS Contract: Dec 19 $2.5C Entry: 2.50 Exit: 3.69 Return: +47.74% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
trabsemloh
trabsemloh Dec. 4 at 10:16 PM
$ANVS If this goes good will use funds to invest in NEXT may have to wait c couple years but I think this will pay off due to increase energy demands
1 · Reply
StMichaelTwits
StMichaelTwits Dec. 4 at 6:47 PM
$ANVS Feels like a Friday..🤣
0 · Reply
Kayhless
Kayhless Dec. 4 at 6:04 PM
$ANVS No volume people are just sitting on their hands.
0 · Reply
StMichaelTwits
StMichaelTwits Dec. 4 at 5:48 PM
$ANVS very thin after 4.78
1 · Reply
_HUNTERXHUNTER_
_HUNTERXHUNTER_ Dec. 4 at 5:16 PM
$ANVS
0 · Reply
LionNoRichy
LionNoRichy Dec. 4 at 4:40 PM
$ANVS ooof shall we load or not - dilemma
1 · Reply
moazkhan
moazkhan Dec. 4 at 4:12 PM
$ANVS I believe full data wont be released until FDA review.
1 · Reply
doyoujetset
doyoujetset Dec. 4 at 4:01 PM
$ANVS consolidation at the 5 year downtrend line about done right into PD updates⏳
0 · Reply
Latest News on ANVS
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Dec 3, 2025, 8:00 AM EST - 1 day ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Annovis Announces Two Presentations at the CTAD 2025 Conference

Nov 24, 2025, 8:00 AM EST - 10 days ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Nov 18, 2025, 8:00 AM EST - 16 days ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients

Nov 17, 2025, 1:07 PM EST - 17 days ago

Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Nov 17, 2025, 8:00 AM EST - 17 days ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 8:00 AM EST - 22 days ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 27, 2025, 8:00 AM EDT - 5 weeks ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Oct 15, 2025, 5:15 PM EDT - 7 weeks ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Oct 10, 2025, 8:31 AM EDT - 7 weeks ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Oct 9, 2025, 7:30 AM EDT - 2 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 25, 2025, 7:30 AM EDT - 2 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 16, 2025, 7:30 AM EDT - 2 months ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 3 months ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 26, 2025, 8:00 AM EDT - 5 months ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 19, 2025, 6:30 AM EDT - 6 months ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Annovis to Host Webinar and Live Q&A on June 24, 2025

Jun 5, 2025, 8:00 AM EDT - 6 months ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:30 PM EDT - 7 months ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Apr 29, 2025, 8:00 AM EDT - 7 months ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 27, 2025, 4:30 PM EDT - 9 months ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 25, 2025, 8:00 AM EDT - 9 months ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 21, 2025, 5:05 PM EDT - 9 months ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Mar 11, 2025, 8:00 AM EDT - 9 months ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 19, 2025, 8:30 AM EST - 10 months ago

Annovis to Host Patients' Live Forum on February 27, 2025

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 7, 2025, 8:00 AM EST - 10 months ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 5, 2025, 8:00 AM EST - 10 months ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 4, 2025, 4:31 PM EST - 10 months ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 10 months ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Annovis Bio, Inc. Announces Proposed Public Offering

Jan 31, 2025, 8:14 PM EST - 10 months ago

Annovis Bio, Inc. Announces Proposed Public Offering

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Jan 14, 2025, 8:00 AM EST - 11 months ago

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

Dec 5, 2024, 8:30 AM EST - 1 year ago

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

/C O R R E C T I O N -- Today's Marketplace/

Dec 4, 2024, 2:21 PM EST - 1 year ago

/C O R R E C T I O N -- Today's Marketplace/

Annovis to Host Year-End Investor Webcast on December 11, 2024

Nov 25, 2024, 8:00 AM EST - 1 year ago

Annovis to Host Year-End Investor Webcast on December 11, 2024

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

Oct 31, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Oct 15, 2024, 8:00 AM EDT - 1 year ago

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

Oct 3, 2024, 8:30 AM EDT - 1 year ago

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Jul 24, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Annovis stock more than doubled on Tuesday: what happened?

Jul 2, 2024, 4:13 PM EDT - 1 year ago

Annovis stock more than doubled on Tuesday: what happened?

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Jul 2, 2024, 1:57 PM EDT - 1 year ago

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

Jun 26, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

Jun 11, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

Annovis Announces New Publication in a Peer-Reviewed Journal

May 21, 2024, 7:30 AM EDT - 1 year ago

Annovis Announces New Publication in a Peer-Reviewed Journal

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

May 16, 2024, 7:02 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

May 16, 2024, 3:09 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

femtomolar
femtomolar Dec. 5 at 4:15 AM
$ANVS The moment I have been waiting for 3 years, thought it would be Biden. Maria, this is the chance you redeem yourself! https://x.com/RepKamlagerDove/status/1996695410174218641?s=20
0 · Reply
Iightning
Iightning Dec. 5 at 12:41 AM
1ightning® Premium Options Alert (Actionable) Ticker: $ANVS Contract: Dec 19 $2.5C Entry: 2.50 Exit: 3.69 Return: +47.74% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
trabsemloh
trabsemloh Dec. 4 at 10:16 PM
$ANVS If this goes good will use funds to invest in NEXT may have to wait c couple years but I think this will pay off due to increase energy demands
1 · Reply
StMichaelTwits
StMichaelTwits Dec. 4 at 6:47 PM
$ANVS Feels like a Friday..🤣
0 · Reply
Kayhless
Kayhless Dec. 4 at 6:04 PM
$ANVS No volume people are just sitting on their hands.
0 · Reply
StMichaelTwits
StMichaelTwits Dec. 4 at 5:48 PM
$ANVS very thin after 4.78
1 · Reply
_HUNTERXHUNTER_
_HUNTERXHUNTER_ Dec. 4 at 5:16 PM
$ANVS
0 · Reply
LionNoRichy
LionNoRichy Dec. 4 at 4:40 PM
$ANVS ooof shall we load or not - dilemma
1 · Reply
moazkhan
moazkhan Dec. 4 at 4:12 PM
$ANVS I believe full data wont be released until FDA review.
1 · Reply
doyoujetset
doyoujetset Dec. 4 at 4:01 PM
$ANVS consolidation at the 5 year downtrend line about done right into PD updates⏳
0 · Reply
ScottHopko
ScottHopko Dec. 4 at 2:13 PM
$ANVS Ask size $5.05 (9:13am)
0 · Reply
StMichaelTwits
StMichaelTwits Dec. 4 at 1:44 PM
$ANVS PR Monday, most likely...👇😘 Presentation details: Title: Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson’s disease dementia patients Presenter: Maria Maccecchini, Ph.D., President and CEO Format: Poster guided tour Time of presentation: December 5, 6:15 p.m. PST
0 · Reply
_HUNTERXHUNTER_
_HUNTERXHUNTER_ Dec. 4 at 1:31 PM
$ANVS let's go! $5 on deck!
0 · Reply
ScottHopko
ScottHopko Dec. 4 at 12:38 PM
$ANVS https://www.ad-hoc-news.de/boerse/news/ueberblick/annovis-bio-s-parkinson-s-candidate-shows-potential-for-cognitive/68407397
1 · Reply
Limcheese22
Limcheese22 Dec. 4 at 12:08 PM
$ANVS if there is partnership announcement . Wonder where is price level will be?
3 · Reply
To_De_Moon
To_De_Moon Dec. 4 at 11:39 AM
$ANVS lets gets nice PR soon
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 4:19 AM
Enter: $ANVS Calls Strike Price: $6 Expiry Date: DEC 26 2025 Buy in Price: $0.25 - $2.00 Sell Price: $0.56 Profit : +126% (Turn every $1 into $2.26) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
ITrustno1
ITrustno1 Dec. 3 at 11:55 PM
$ANVS http://annovisbio.com/pipeline
1 · Reply
aliliimr
aliliimr Dec. 3 at 10:22 PM
$ANVS Alzheimer's ph3: Study Start (Actual) 2025-02-04 Primary Completion (Estimated) 2027-12 Study Completion (Estimated) 2028-06
0 · Reply
clearvision
clearvision Dec. 3 at 10:16 PM
$ANVS i think somebody is looking!
0 · Reply
ScottHopko
ScottHopko Dec. 3 at 5:54 PM
$ANVS Looking at the charts, we may hit 4.99 by the end of the day. Looks strong.
0 · Reply
LionNoRichy
LionNoRichy Dec. 3 at 5:28 PM
$ANVS I want to buy moreeee but my exp here isn't good xd
1 · Reply